Lomerizine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584550

CAS#: 101477-55-8

Description: Lomerizine is a diphenylmethylpiperazine Ca2+ channel blocker that helps prevent migraines.

Chemical Structure

img
Lomerizine
CAS# 101477-55-8
Instruction

Theoretical Analysis

MedKoo Cat#: 584550
Name: Lomerizine
CAS#: 101477-55-8
Chemical Formula: C27H30F2N2O3
Exact Mass: 468.22
Molecular Weight: 468.545
Elemental Analysis: C, 69.21; H, 6.45; F, 8.11; N, 5.98; O, 10.24

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Lomerizine

IUPAC/Chemical Name: 1-(Bis(p-fluorophenyl)-methyl)-4-(2,3,4-trimethoxybenzyl)piperazine

InChi Key: JQSAYKKFZOSZGJ-UHFFFAOYSA-N

InChi Code: InChI=1S/C27H30F2N2O3/c1-32-24-13-8-21(26(33-2)27(24)34-3)18-30-14-16-31(17-15-30)25(19-4-9-22(28)10-5-19)20-6-11-23(29)12-7-20/h4-13,25H,14-18H2,1-3H3

SMILES Code: COC1=CC=C(C(OC)=C1OC)CN2CCN(C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 468.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ren Y, Liu T, Song G, Hu Y, Liang J. Determination of lomerizine in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Feb 1;947-948:96-102. doi: 10.1016/j.jchromb.2013.12.026. Epub 2013 Dec 26. PubMed PMID: 24412691.

2: Tran LT, Gentil BJ, Sullivan KE, Durham HD. The voltage-gated calcium channel blocker lomerizine is neuroprotective in motor neurons expressing mutant SOD1, but not TDP-43. J Neurochem. 2014 Aug;130(3):455-66. doi: 10.1111/jnc.12738. Epub 2014 May 9. PubMed PMID: 24716897.

3: Ishii M, Katoh H, Takagi M, Kawamura M, Shimizu S. Influence of the Tohoku-Pacific Ocean earthquake and its aftershocks on the response to prophylactic therapy with lomerizine in patients with migraine in Tokyo: a retrospective study. Eur Neurol. 2014;71(5-6):252-8. doi: 10.1159/000357209. Epub 2014 Feb 5. PubMed PMID: 24503777.

4: Ishii M, Katoh H, Kurihara T, Kawamura M, Shimizu S. Characteristics of inconsistent responders to prophylaxis therapy with lomerizine in patients with migraine: a retrospective study in Japan. J Neurol Sci. 2013 Dec 15;335(1-2):118-23. doi: 10.1016/j.jns.2013.09.007. Epub 2013 Sep 12. PubMed PMID: 24074550.

5: Furuishi T, Kato Y, Fukami T, Suzuki T, Endo T, Nagase H, Ueda H, Tomono K. Effect of terpenes on the skin permeation of lomerizine dihydrochloride. J Pharm Pharm Sci. 2013;16(4):551-63. PubMed PMID: 24210063.

6: Inoue Y, Yabe T. Lomerizine therapy for the treatment of benign paroxysmal vertigo of childhood transitioning into atypical basilar migraine: A case report. Exp Ther Med. 2013 Jun;5(6):1573-1575. Epub 2013 Apr 2. PubMed PMID: 23837033; PubMed Central PMCID: PMC3702696.

7: Okano M, Thevis M, Sato M, Kageyama S. Analytical detection of trimetazidine produced by metabolic conversion of lomerizine in doping control analysis. Drug Test Anal. 2016 Aug;8(8):869-74. doi: 10.1002/dta.1893. Epub 2015 Nov 11. PubMed PMID: 26560081.

8: Ishii M, Iizuka R, Kiuchi Y, Mori Y, Shimizu S. Neuroprotection by lomerizine, a prophylactic drug for migraine, against hydrogen peroxide-induced hippocampal neurotoxicity. Mol Cell Biochem. 2011 Dec;358(1-2):1-11. doi: 10.1007/s11010-011-0913-3. Epub 2011 Jun 9. PubMed PMID: 21656126.

9: Shimizu H, Nagami S, Takahashi N. [A case of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) in which lomerizine hydrochloride was suggested to prevent recurrent stroke]. Rinsho Shinkeigaku. 2014;54(1):22-6. Japanese. PubMed PMID: 24429644.

10: Ito Y, Nakamura S, Tanaka H, Tsuruma K, Shimazawa M, Araie M, Hara H. Lomerizine, a Ca2+ channel blocker, protects against neuronal degeneration within the visual center of the brain after retinal damage in mice. CNS Neurosci Ther. 2010 Apr;16(2):103-14. doi: 10.1111/j.1755-5949.2009.00081.x. Epub 2009 Sep 24. PubMed PMID: 19788586.

11: Ishii M, Kobayashi S, Ohkura M, Yamamoto R, Shimizu S, Kiuchi Y. Inhibitory effect of lomerizine, a prophylactic drug for migraines, on serotonin-induced contraction of the basilar artery. J Pharmacol Sci. 2009 Oct;111(2):221-5. Epub 2009 Sep 26. PubMed PMID: 19783864.

12: Toriu N, Akaike A, Yasuyoshi H, Zhang S, Kashii S, Honda Y, Shimazawa M, Hara H. Lomerizine, a Ca2+ channel blocker, reduces glutamate-induced neurotoxicity and ischemia/reperfusion damage in rat retina. Exp Eye Res. 2000 Apr;70(4):475-84. PubMed PMID: 10865996.

13: Watano T, Hara H, Sukamoto T. Inhibitory effect of lomerizine, a diphenylpiperazine Ca2+-channel blocker, on Ba2+ current through voltage-gated Ca2+ channels in PC12 cells. Jpn J Pharmacol. 1997 Oct;75(2):209-13. PubMed PMID: 9414039.

14: Hara H, Shimazawa M, Sasaoka M, Yamada C, Iwakura Y, Sakai T, Maeda Y, Yamaguchi T, Sukamoto T, Hashimoto M. Selective effects of lomerizine, a novel diphenylmethylpiperazine Ca2+ channel blocker, on cerebral blood flow in rats and dogs. Clin Exp Pharmacol Physiol. 1999 Nov;26(11):870-6. PubMed PMID: 10561807.

15: Shiraki N, Hamada A, Ohmura T, Tokunaga J, Oyama N, Nakano M. Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine. Biol Pharm Bull. 2001 May;24(5):555-7. PubMed PMID: 11379779.

16: Karim Z, Sawada A, Kawakami H, Yamamoto T, Taniguchi T. A new calcium channel antagonist, lomerizine, alleviates secondary retinal ganglion cell death after optic nerve injury in the rat. Curr Eye Res. 2006 Mar;31(3):273-83. PubMed PMID: 16531285.

17: Selt M, Bartlett CA, Harvey AR, Dunlop SA, Fitzgerald M. Limited restoration of visual function after partial optic nerve injury; a time course study using the calcium channel blocker lomerizine. Brain Res Bull. 2010 Mar 16;81(4-5):467-71. doi: 10.1016/j.brainresbull.2009.11.004. Epub 2009 Nov 11. PubMed PMID: 19913075.

18: Toriu N, Sasaoka M, Shimazawa M, Sugiyama T, Hara H. Effects of lomerizine, a novel Ca2+ channel blocker, on the normal and endothelin-1-disturbed circulation in the optic nerve head of rabbits. J Ocul Pharmacol Ther. 2001 Apr;17(2):131-49. PubMed PMID: 11324981.

19: Fitzgerald M, Bartlett CA, Evill L, Rodger J, Harvey AR, Dunlop SA. Secondary degeneration of the optic nerve following partial transection: the benefits of lomerizine. Exp Neurol. 2009 Mar;216(1):219-30. doi: 10.1016/j.expneurol.2008.11.026. Epub 2008 Dec 11. PubMed PMID: 19118550.

20: Tamaki Y, Araie M, Fukaya Y, Nagahara M, Imamura A, Honda M, Obata R, Tomita K. Effects of lomerizine, a calcium channel antagonist, on retinal and optic nerve head circulation in rabbits and humans. Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4864-71. PubMed PMID: 14578410.